HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.
Sign Up to like & getrecommendations! Published in 2023 at "HLA"
DOI: 10.1111/tan.15008
Abstract: Recently, the randomized phase-II Triton study demonstrated that mesenchymal stromal cell (MSC) therapy facilitated early tacrolimus withdrawal in living donor kidney transplant recipients. The current sub-study analyzed formation of de novo donor-specific HLA antibodies (dnDSA)… read more here.
Keywords: hla eplet; hla; eplet; mismatch load ... See more keywords